Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507931 | 0.78 | KMT2A (0.50) | ALDH1A1HTTSMN1; SMN2L3MBTL1ATM | |
| SCHEMBL7810345 | 0.75 | PTGS2 (0.60) | CES2CES1PTGS2 | |
| SCHEMBL1002846 | 0.75 | CES2 (0.53) | MAOAMAOBVNN1ACHECES2 | |
| SCHEMBL22158837 | 0.75 | KMT2A (0.53) | MAOAMAOBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL27786436 | 0.75 | KMT2A (0.54) | ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7967901 | 0.74 | CES2 (0.73) | VNN1CES2CES1RAB9A | |
| SCHEMBL4952656 | 0.74 | CA2 (0.58) | PTGS2ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL2883300 | 0.74 | CES2 (0.44) | MAOAMAOBVNN1ACHECES2 | |
| SCHEMBL780272 | 0.72 | CA2 (0.48) | MAOB | |
| SCHEMBL507343 | 0.72 | KMT2A (0.48) | VNN1ALDH1A1HTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | MAOA 577/4885MAOB 225/4885VNN1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.